Luis Paz-Ares1, Tudor-Eliade Ciuleanu2, Manuel Cobo3, Michael Schenker4, Bogdan Zurawski5, Juliana Menezes6, Eduardo Richardet7, Jaafar Bennouna8, Enriqueta Felip9, Oscar Juan-Vidal10, Aurelia Alexandru11, Hiroshi Sakai12, Alejo Lingua13, Pamela Salman14, Pierre-Jean Souquet15, Pedro De Marchi16, Claudio Martin17, Maurice Pérol18, Arnaud Scherpereel19, Shun Lu20, Thomas John21, David P Carbone22, Stephanie Meadows-Shropshire23, Shruti Agrawal23, Abderrahim Oukessou23, Jinchun Yan23, Martin Reck24. 1. Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Universidad Complutense & CiberOnc, Madrid, Spain. Electronic address: lpazaresr@seom.org. 2. Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania. 3. Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. 4. SF Nectarie Oncology Center, Craiova, Romania. 5. Ambulatorium Chemioterapii, Bydgoszcz, Poland. 6. Hospital Nossa Senhora Da Conceição, Porto Alegre, Brazil. 7. Instituto Oncológico De Córdoba, Córdoba, Argentina. 8. Thoracic Oncology Unit, University Hospital of Nantes and INSERM, CRCINA, Nantes, France. 9. Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain. 10. Hospital Universitario La Fe, Valencia, Spain. 11. Institute of Oncology Prof Dr Alexandru Trestioreanu Bucha, Bucharest, Romania. 12. Saitama Cancer Center, Saitama, Japan. 13. Instituto Medico Rio Cuarto SA, Córdoba, Argentina. 14. Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile. 15. Hôpital Lyon Sud, Lyon, Pierre Bénite, France. 16. Barretos Cancer Hospital, Barretos, Brazil. 17. Instituto Alexander Fleming, Buenos Aires, Argentina. 18. Léon Bérard Cancer Center, Lyon, France. 19. Pulmonary and Thoracic Oncology, University of Lille, CHU Lille, INSERM U1189, OncoThAI, Lille, France. 20. Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, China. 21. Austin Hospital, Heidelberg, VIC, Australia. 22. The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 23. Bristol Myers Squibb, Princeton, NJ, USA. 24. Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany.
Abstract
BACKGROUND: First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit. METHODS: This randomised, open-label, phase 3 trial was done at 103 hospitals in 19 countries. Eligible patients were aged 18 years or older with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) by an interactive web response system via permuted blocks (block size of four) to nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles; experimental group), or chemotherapy alone (every 3 weeks for four cycles; control group). Randomisation was stratified by tumour histology, sex, and PD-L1 expression. The primary endpoint was overall survival in all randomly assigned patients. Safety was analysed in all treated patients. Results reported here are from a pre-planned interim analysis (when the study met its primary endpoint) and an exploratory longer-term follow-up analysis. This study is active but no longer recruiting patients, and is registered with ClinicalTrials.gov, number NCT03215706. FINDINGS:Between Aug 24, 2017, and Jan 30, 2019, 1150 patients were enrolled and 719 (62·5%) randomly assigned to nivolumab plus ipilimumab with two cycles of chemotherapy (n=361 [50%]) or four cycles of chemotherapy alone (n=358 [50%]). At the pre-planned interim analysis (median follow-up 9·7 months [IQR 6·4-12·8]), overall survival in all randomly assigned patients was significantly longer in the experimental group than in the control group (median 14·1 months [95% CI 13·2-16·2] vs 10·7 months [9·5-12·4]; hazard ratio [HR] 0·69 [96·71% CI 0·55-0·87]; p=0·00065). With 3·5 months longer median follow-up (median 13·2 months [IQR 6·4-17·0]), median overall survival was 15·6 months (95% CI 13·9-20·0) in the experimental group versus 10·9 months (9·5-12·6) in the control group (HR 0·66 [95% CI 0·55-0·80]). The most common grade 3-4 treatment-related adverse events were neutropenia (in 24 [7%] patients in the experimental group vs 32 [9%] in the control group), anaemia (21 [6%] vs 50 [14%]), diarrhoea (14 [4%] vs two [1%]), increased lipase (22 [6%] vs three [1%]), and asthenia (tjree [1%] vs eight [2%]). Serious treatment-related adverse events of any grade occurred in 106 (30%) patients in the experimental group and 62 (18%) in the control group. Seven (2%) deaths in the experimental group (acute kidney failure, diarrhoea, hepatotoxicity, hepatitis, pneumonitis, sepsis with acute renal insufficiency, and thrombocytopenia; one patient each) and six (2%) deaths in the control group (anaemia, febrile neutropenia, pancytopenia, pulmonary sepsis, respiratory failure, and sepsis; one patient each) were treatment related. INTERPRETATION:Nivolumab plus ipilimumab with two cycles of chemotherapy provided a significant improvement in overall survival versus chemotherapy alone and had a favourable risk-benefit profile. These data support this regimen as a new first-line treatment option for patients with advanced NSCLC. FUNDING: Bristol Myers Squibb.
RCT Entities:
BACKGROUND: First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether the addition of a limited course (two cycles) of chemotherapy to this combination would further enhance the clinical benefit. METHODS: This randomised, open-label, phase 3 trial was done at 103 hospitals in 19 countries. Eligible patients were aged 18 years or older with treatment-naive, histologically confirmed stage IV or recurrent NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) by an interactive web response system via permuted blocks (block size of four) to nivolumab (360 mg intravenously every 3 weeks) plus ipilimumab (1 mg/kg intravenously every 6 weeks) combined with histology-based, platinum doublet chemotherapy (intravenously every 3 weeks for two cycles; experimental group), or chemotherapy alone (every 3 weeks for four cycles; control group). Randomisation was stratified by tumour histology, sex, and PD-L1 expression. The primary endpoint was overall survival in all randomly assigned patients. Safety was analysed in all treated patients. Results reported here are from a pre-planned interim analysis (when the study met its primary endpoint) and an exploratory longer-term follow-up analysis. This study is active but no longer recruiting patients, and is registered with ClinicalTrials.gov, number NCT03215706. FINDINGS: Between Aug 24, 2017, and Jan 30, 2019, 1150 patients were enrolled and 719 (62·5%) randomly assigned to nivolumab plus ipilimumab with two cycles of chemotherapy (n=361 [50%]) or four cycles of chemotherapy alone (n=358 [50%]). At the pre-planned interim analysis (median follow-up 9·7 months [IQR 6·4-12·8]), overall survival in all randomly assigned patients was significantly longer in the experimental group than in the control group (median 14·1 months [95% CI 13·2-16·2] vs 10·7 months [9·5-12·4]; hazard ratio [HR] 0·69 [96·71% CI 0·55-0·87]; p=0·00065). With 3·5 months longer median follow-up (median 13·2 months [IQR 6·4-17·0]), median overall survival was 15·6 months (95% CI 13·9-20·0) in the experimental group versus 10·9 months (9·5-12·6) in the control group (HR 0·66 [95% CI 0·55-0·80]). The most common grade 3-4 treatment-related adverse events were neutropenia (in 24 [7%] patients in the experimental group vs 32 [9%] in the control group), anaemia (21 [6%] vs 50 [14%]), diarrhoea (14 [4%] vs two [1%]), increased lipase (22 [6%] vs three [1%]), and asthenia (tjree [1%] vs eight [2%]). Serious treatment-related adverse events of any grade occurred in 106 (30%) patients in the experimental group and 62 (18%) in the control group. Seven (2%) deaths in the experimental group (acute kidney failure, diarrhoea, hepatotoxicity, hepatitis, pneumonitis, sepsis with acute renal insufficiency, and thrombocytopenia; one patient each) and six (2%) deaths in the control group (anaemia, febrile neutropenia, pancytopenia, pulmonary sepsis, respiratory failure, and sepsis; one patient each) were treatment related. INTERPRETATION:Nivolumab plus ipilimumab with two cycles of chemotherapy provided a significant improvement in overall survival versus chemotherapy alone and had a favourable risk-benefit profile. These data support this regimen as a new first-line treatment option for patients with advanced NSCLC. FUNDING: Bristol Myers Squibb.
Authors: Jonathan D Schoenfeld; Anita Giobbie-Hurder; Srinika Ranasinghe; Katrina Z Kao; Ana Lako; Junko Tsuji; Yang Liu; Ryan C Brennick; Ryan D Gentzler; Carrie Lee; Joleen Hubbard; Susanne M Arnold; James L Abbruzzese; Salma K Jabbour; Nataliya V Uboha; Kevin L Stephans; Jennifer M Johnson; Haeseong Park; Liza C Villaruz; Elad Sharon; Howard Streicher; Mansoor M Ahmed; Hayley Lyon; Carrie Cibuskis; Niall Lennon; Aashna Jhaveri; Lin Yang; Jennifer Altreuter; Lauren Gunasti; Jason L Weirather; Raymond H Mak; Mark M Awad; Scott J Rodig; Helen X Chen; Catherine J Wu; Arta M Monjazeb; F Stephen Hodi Journal: Lancet Oncol Date: 2022-01-13 Impact factor: 41.316
Authors: John M Varlotto; Zhuoxin Sun; Bonnie Ky; Jenica Upshaw; Sharyn I Katz; Thomas J Fitzgerald; Heather Wakelee; Maximilian Diehn; David A Mankoff; Christine Lovely; Chandra Belani; Kurt Oettel; Gregory Masters; Suresh Ramalingam; Nathan A Pennell Journal: Oncologist Date: 2021-03-11
Authors: Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244